Trial Profile
Safety and pharmacokinetics of tabalumab in patients with rheumatoid arthritis or systemic lupus erythematosus
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 17 Dec 2015
Price :
$35
*
At a glance
- Drugs Tabalumab (Primary)
- Indications Rheumatoid arthritis; Systemic lupus erythematosus
- Focus Adverse reactions; Pharmacokinetics
- 17 Dec 2015 Status changed from not stated to completed.
- 17 Dec 2015 New trial record
- 09 Dec 2015 Results published in the British Journal of Clinical Pharmacology